Tranylcypromine (MAOI) in Attention Deficit Hyperactivity Disorder in Children

M.H. El-Defrawi

Tranylcypromine (MAOI) was administered to twenty seven children (mean age 7.4 years ± 3.2) with DSM-III-R Attention Deficit Hyperactivity Disorder (ADHD). Comparison of pre-and post-medication behavioral assessments using the Conners Abbreviated Hyperactivity Rating Scale showed a statistically significant difference (P< 0.001) which suggests that tranylcypromine could be an effective antihyperactivity drug. (Egypt. J. Psychiat., 1992, 15:66-70).

Introduction

It is generally accepted that attention deficit hyperactivity disorder (ADHD) is a heterogeneous disorder. The comorbidity of attention deficit hyperactivity disorder (ADHD) occurs in combination with other psychiatric disorders of childhood including conduct disorders, mental retardation, pervasive developmental disorders, anxiety disorders and epilepsy. Children with ADHD respond to a variety of drugs including neuroleptics, antidepressants, and anticonvulsants (Biederman et al., 1989, Evans et al., 1987, Ornitz, 1985). Antidepressants and neuroleptics when used in the treatment of ADHD are not without deleterious side effects (Biederman, 1991; Perry et al., 1985).

Psychostimulant intervention remains the most common treatment for Attention Deficit Hyperactivity Disorder in children (Rapport et al., 1986, Solanto and Wender, 1989 Strayhorn et al., 1988; Birmaher et. al., 1988). Zametkin et al., (1985) have shown that monoamine oxidase inhibitors (MAOIs) have immediate, clinically significant benefits and were clinically indistinguishable from dextroamphetamine.

Previous studies of MAOIs in childhood psychiatric disorders suggested its effectiveness in depressed and phobic children (Kelly et al., 1970 and, Frommer, 1967).

Psychostimulants are not well recognized as the drug of choice in the treatment of ADHD in Egyptian children because these agents are controlled drugs and their prescription is extremely restricted and even prohibited. Because psychostimulants (dextroamphetamine and methylphenidate) are not available in Egypt, this study was designed as an open clinical drug trial to evaluate the efficacy of tranylcypromine in Egyptian children with hyperactivity (ADHD).

Subjects and Method

Twenty seven children (23 boys and 4 girls) aged 4-12 years (mean 7.4 ± 3.2 years), with moderate to severe hyperactivity diagnosed according to the DSM-III-R criteria of ADHD, were behaviourally assessed regardless of concomitant diagnoses. All of the children went through a 1-month period of assessment during which diagnostic evaluation and laboratory studies were completed. The initial evaluation included a complete medical pediatric examination and psychiatric, psychological, neurological, speech, and hearing evaluation. Labora-
Tranylcypromine (MAOI) in A.D.H.D.

Two tailed paired t test was carried out.

**Results**

Comparison of the pre (mean 22.9 ±3.1) and post (mean 14.9 ±4.5) total scores of Conners Rating Scale revealed a statistically significant difference (p<0.001) (Figure 1). It was observed that the drug reduces hyperactivity with short onset and offset of action in most children. Therefore, doses had to be adjusted and administered twice per day (in the morning and at noon time).

Children with nocturnal enuresis were almost completely dry during tranylcypromine treatment. In only three children, tranylcypromine was discontinued. In the first, a 5-year-old girl developed hyperactivity, irritability, and insomnia with tachycardia.

In the other two children, headache and loss of appetite were the reason for discontinuation.

Side effects within first week of treatment included loss of appetite (81.4%), anorexia (51.8%), insomnia (51.8%), decreased weight (48.1%), headache (25.9%), drowsiness (18.5%), depressed mood (11.1%), dullness (11.1%), abdominal pain (11.1%), agitation (7.4%) and rebound hyperactivity (11.1%). However, most of these undesirable effects disappeared within 2-3 weeks of drug administration.

**Discussion**

The results here are consistent with previous reports indicating the efficacy of tranylcypromine in reducing the severity and intensity of ADHD in children (Zametkin et al., 1985).

While this study has strengths associated with the use of a reliable and valid assessment tool before and after the drug study period, the recording of drug -

---

induced side effects systematically, and the trial of an available drug in the Egyptian market to treat one of the most common psychiatric disorders in children, it is nonetheless limited in several ways:

(1) parents ratings were not blind, (2) there were no controls, (3) children were a heterogeneous group of diagnoses sharing hyperactivity as a common feature.

Treatment of attention deficit hyperactivity problems is very crucial because this disorder has been reported to result or be associated in academic failure and disturbed social interactions with family and peers (McGee and Share, 1988; Barkley, 1988). Treatment with stimulant has resulted in significant improvement in social and academic functioning.

The present study, although uncontrolled, demonstrates that tranylcypromine is effective in reducing hyperactivity in a heterogeneous group of ADHD children. However, in interpreting these results, certain cautions are in order, specifically the use of parents ratings as the sole source of assessment of behavioral change.

Second, results could be due to type II error associated with the modest sample size.

Tranylcypromine produced significant behavioral changes which were apparent immediately and within half an hour to an hour from drug administration. However, this beneficial effect lasts from two to four hours after which the child's behavior returned to the baseline or the pretreatment threshold. In only few children, there were reports suggesting the occurrence of a rebound phenomena. This means that the child's behavior escalates slightly higher than the pretreatment level. In these cases, parents were advised to give the second dose about three hours after the first one.

Some children initially responded to tranylcypromine by sleeping, but this calming effect disappeared within few days of treatment continuation. However, in most children the reduction in the level of hyperactivity was striking in contrast to their usual hyperactivity level. In four children, the calming effect of the drug was associated with a state of fear of separation from the parent. In one child the drug has produced a clinging and attachment behaviour where the child followed his mother allover the house.

The emerged undesirable effects are in contrast of those of Zametkin et al., (1985) and suggest that caution should be considered in case selection and drug monitoring. Treatment with tranylcypromine should be preceded with a baseline evaluation and with a test dose of 5 mg or 10 mg depending on the size of the child.

The clinical effectiveness and toxicity of tranylcypromine appears to be dose related. However, since there is a wide individual variability in drug response several recommendation can be made to monitor the antihyperactivity effects of
Tranylcypromine including regular check of the blood pressure, heart rate, weight, sleeping hours and level of hyperactivity.

Biochemical etiological speculations suggest that hyperkinetic disorder results from selective deficiency of dopamine in the central nervous system. It is possible that tranylcypromine functions as dopamine agonist, simply increasing CNS dopamine concentration and alleviating the clinical syndrome. However, we agree with Zametkin et al., (1985) that the effect of tranylcypromine in ADHD might be mediated through multiple neurotransmitter changes rather than a single selective alteration of a single amine.

Moreover, future studies should compare behavioral, cognitive and social effects of different dosages of tranylcypromine using multiple measures and cross-over controlled technique.

References


Tranylcypromine (IMAO) dans le Trouble: Déficite de l'Attention avec Hyperactivité chez les Enfants

Un groupe de 27 enfants (moyenne d'âge 7.4 ± 3.2) ayant le diagnostique de déficite de l'attention avec hyperactivité selon le DSM III-R a été évaluer avant et après l'administration d'une IMAO, tranylcypromine. Les résultats, évaluer à l'aide de l'échelle abrégée de Conners, ont montré une différence statistiquement significative (p<0.001) suggerant que la tranylcypromine pourrait être un traitement efficace du syndrome d'hyperactivité.